Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596866 · ClinicalTrials.gov registry record · Phase 3
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 248
- Enrollment target
NCT03596866 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 248 participants.
The verdict
NCT03596866, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 248 participants
- Enrollment target
Study Summary
Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: * Brigatinib tablets * Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.
Interventions
- DRUG Alectinib
- DRUG Brigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2019-04-19 |
| Est. Completion | 2024-09-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596866
The ClinicalTrials.gov registry entry for NCT03596866 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alectinib is the first listed.
NCT03596866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596866 about?
NCT03596866 is a clinical study titled "A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer". Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tum...
What is the current status of trial NCT03596866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 248 participants. The study started on 2019-04-19. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT03596866?
The interventions under investigation include: Alectinib (DRUG), Brigatinib (DRUG).
Who is sponsoring clinical trial NCT03596866?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.